Biostatistics Built Around Biotech Companies
Evestia Clinical operates as an extension of the sponsor organization, providing experienced Biostatisticians and specialist Statistical Programrs who engage proactively throughout development. Clinical development teams gain embedded scientific collaboration, integrated biometrics and the strategic alignment that confident decision-making requires.
Experienced Biostatisticians
Phase I–IV & Post-Marketing specialists who provide scientific partnership throughout the program through embedded, collaborative engagement.
Regulatory-focused planning
Statistical strategies built around FDA, EMA and MHRA expectations from the first protocol discussion.
Integrated biometrics
CDM, Biostatistics and Medical Writing working in close alignment throughout development, as one integrated scientific team.
Flexible delivery models
Full-Service CRO or embedded FSP resource, scaled to your program requirements and funding milestones.
Biostatistics Expertise
Phase I–IV & Post-Marketing coverage, CDISC-compliant submission capability and integrated Data Management support, reflecting sustained Biostatistics delivery across complex programs from early development through to global registration.
Phase I–IV
Statistical Support
Early development through post-marketing
CDISC-Compliant
Submission Outputs
Supporting regulatory submissions
Integrated
Data Management & Biostatistics
End-to-end analytical support
Global
Regulatory Submission Support
Multi-region development programs
Expert Biostatistics Supporting Regulatory Decisions and Clinical Development Success
Modern clinical development increasingly relies on adaptive designs, biomarker-driven endpoints, multi-regional studies and integrated statistical expertise. Strong biostatistical planning supports regulatory confidence from the outset, ensuring studies are designed to answer the scientific questions development decisions and submissions depend on. Biostatistics is a critical function within Clinical Data Management and Clinical Operations, working alongside Medical Affairs, Regulatory Affairs and Medical Writing throughout the development lifecycle.
Delivered within an integrated Full-Service CRO model, biostatistical and programming teams support organizations from protocol development and sample size calculations through to final Clinical Study Reports and regulatory submissions. As a specialist Biotech CRO, Evestia Clinical transforms study data into reliable evidence that supports development decisions, funding milestones and global approval.
Why Biostatistics Matters
Strong study design, reliable evidence and informed decision-making are the foundation of successful clinical development and regulatory submissions. Statistical quality gives sponsors the scientific confidence to advance programs, secure funding and build submissions that withstand regulatory review.
Across Phase I, Phase II and Phase III, statistical quality is a direct driver of program success. Clinical teams that invest in experienced statistical expertise throughout development, rather than only at analysis, strengthen study design, improve submission quality and give their therapies the strongest possible chance of reaching the patients who need them.
What Is Biostatistics?
Biostatistics is the scientific framework that ensures clinical evidence is reliable. It transforms study data into meaningful evidence that supports regulatory decision-making, and underpins the development strategies, funding decisions and regulatory submissions that follow.
Within clinical trials, Biostatistics ensures studies are designed to answer the scientific questions they are intended to answer, that analytical methodologies are robust and defensible, and that statistical outputs provide the clear, reproducible evidence regulators require.
Biostatistics provides the framework that allows sponsors to answer the critical questions that determine whether a program advances:
- Is the study appropriately designed?
- Is the sample size sufficient?
- Are endpoints statistically valid?
- Are treatment effects clinically meaningful?
- Can the data support regulatory approval?
Robust statistical planning is the scientific foundation that every successful development program is built on, supporting confident decisions and successful submissions.
Why Biostatistics Matters
Reliable statistical evidence gives sponsors the scientific confidence to make informed development decisions and build submissions that withstand regulatory review. Statistical quality is the foundation that separates programs that advance from those that stall.
Sponsors who engage experienced Biostatistics support early, and maintain it throughout the program, build the scientific foundation that supports confident decisions, successful submissions and program progression.
Better Development Decisions
Every critical decision in clinical development, from dose selection to go/no-go milestones, depends on reliable statistical evidence. Early statistical planning gives sponsors the analytical foundation to make confident decisions that protect investment and program momentum.
Stronger Regulatory Confidence
Health authorities expect predefined methodologies, transparent analyses and validated datasets. Robust statistical planning from study inception supports smoother regulatory review, stronger reviewer confidence and submission readiness at every stage.
Confident Statistical Planning
Early involvement of experienced biostatisticians strengthens study design, endpoint selection and analytical strategy from the outset. Sound planning gives sponsors the scientific confidence that data will support development decisions, regulatory review and program progression.
Maximizing Development Value
Every patient enrolled represents scientific and financial investment. Rigorous statistical analysis ensures every data point contributes to reliable evidence, strengthening the program progression and investor confidence that successful development depends on.
Faster Submission Timelines
Efficient statistical planning, validated programming and integrated data management support the transition from database lock to submission-ready outputs, sustaining the development timelines that funding milestones and commercial objectives depend on.
Our Biostatistics Services
Each service is delivered as part of an integrated scientific approach focused on program outcomes and submission readiness.
Statistical Consulting and Study Design
Strong statistical planning creates the scientific framework for successful clinical development. Statistical consulting at program inception ensures protocols are built around scientific questions they can genuinely answer, with endpoints regulators will accept and designs that are operationally achievable. Services include:
- Protocol input
- Endpoint selection
- Study design optimization
- Adaptive design consultation
- Statistical strategy development
Sample Size Calculations
Accurate sample sizing balances scientific objectives, patient considerations and operational efficiency. Right-sized studies generate the evidence regulators require while respecting patient welfare and program budgets. Our teams provide:
- Power calculations
- Sample size determination
- Scenario modeling
- Sensitivity analyses
Appropriate sample size calculations balance scientific objectives with operational and commercial realities from the outset.
Statistical Analysis Plans (SAPs)
Comprehensive Statistical Analysis Plans provide transparent, reproducible analytical frameworks. A well-constructed SAP demonstrates scientific rigor and analytical integrity before unblinding, giving regulatory reviewers the confidence they need. Our teams develop comprehensive SAPs covering:
- Analysis populations
- Endpoint definitions
- Statistical methodologies
- Missing data strategies
- Interim analyses
- Regulatory requirements
Randomization and Trial Design
Robust randomization strengthens scientific validity and treatment comparisons. Carefully designed randomization and trial design eliminate systematic error, ensuring treatment effects observed are real rather than artefacts of study conduct. Our support includes:
- Randomization schedules
- Stratification strategies
- Blinded study designs
- Adaptive trial methodologies
Rigorous design integrity supports the scientific credibility that regulatory approval and investor confidence depend on.
Statistical Programming
Validated programming produces submission-ready outputs that meet global regulatory expectations. CDISC-compliant programming ensures statistical deliverables meet the exact standards the FDA, EMA and MHRA expect. Our programming teams provide:
- SAS® programming
- SDTM dataset generation
- ADaM dataset creation
- TLF production
- Define.xml generation
- Reviewer Guides
All programming is delivered within validated environments. Our teams produce CDISC-compliant outputs including SDTM, ADaM, aCRF and Define.xml documentation to full submission standard.
Interim Analyses
Development decisions made mid-study, from dose selection to program continuation, require reliable evidence at the moment decisions are needed. Well-designed interim analyses give sponsors and Data Monitoring Committees the information to act decisively rather than reactively. Support includes:
- Safety reviews
- Efficacy assessments
- Futility analyses
- Data Monitoring Committee support
Final Statistical Analysis and Reporting
The final analysis is the scientific culmination of every decision, resource and patient contribution made throughout the program. Rigorous, reproducible analysis transforms study data into the regulatory evidence that determines approval outcomes. Our teams support:
- Primary endpoint analysis
- Secondary endpoint analysis
- Subgroup analysis
- Sensitivity analysis
- Clinical Study Reports
Our statistical teams contribute through final reporting from program initiation to completion, ensuring continuity and scientific consistency throughout.
How Evestia Strengthens Biostatistics
Experienced Biostatistics keeps programs moving, with scientific and regulatory priorities addressed proactively so development decisions, submission timelines and program confidence are supported throughout the study.
Complex Study Design
Developing statistically robust protocols that answer the right scientific questions is one of the most consequential decisions in clinical development. Experienced biostatisticians ensure designs are scientifically valid, operationally achievable and aligned with regulatory expectations before the first patient is enrolled.
Regulatory Expectations
The FDA, EMA and MHRA expect pre-specified methodologies, validated datasets and transparent analyses. Sponsors who invest in rigorous statistical planning from study inception are better positioned for regulatory review, with stronger reviewer confidence and smoother approval pathways.
Data Complexity
Modern clinical trials generate data from multiple sources simultaneously: investigator sites, central laboratories, imaging providers, wearables and ePRO systems. Integrated statistical and programming expertise ensures this complexity strengthens, rather than complicates, the analytical foundation sponsors rely on.
Submission Readiness
CDISC-compliant SDTM and ADaM datasets, Define.xml files and Reviewer Guides are core submission deliverables. Sponsors who treat submission readiness as a program-wide discipline produce compliant, analysis-ready outputs that support efficient regulatory review.
Scalable Statistical Resource
Many biotechnology companies manage programs of increasing statistical complexity alongside scientific and commercial priorities. Accessing experienced biostatisticians and statistical programrs through flexible delivery models provides the scientific depth programs require without increasing permanent headcount.
Development Decisions
Go/no-go decisions, dose selection, adaptive design modifications and funding milestone assessments all depend on reliable statistical evidence. Sponsors who invest in expert statistical support throughout their program make better decisions at every stage of development.
Biostatistics for Regulatory Submission Success
The FDA, EMA and MHRA expect transparent statistical methodologies, reproducible analyses and validated datasets. Integrated statistical planning throughout the program lifecycle ensures submission readiness is built from the outset rather than addressed at close-out.
Every deliverable, including CDISC-compliant SDTM and ADaM datasets, SAPs, TLFs, Define.xml files and reporting documentation, is prepared to the exact standards global regulatory reviewers require. Our Global CRO capabilities maintain statistical consistency across multinational programs, working alongside Medical Affairs, Regulatory Affairs, Clinical Data Management and Medical Writing.
Biostatistics Across Every Phase of Development
Statistical priorities evolve throughout development. Evestia Clinical adapts approaches to each phase, from precise safety evaluation frameworks in Phase I, through proof-of-concept analyses that support Phase III investment decisions, to the large-scale validated analyses and global submission packages that registration programs require.
Early-stage development demands precise statistical oversight. Dose escalation decisions, safety signal evaluation and early stopping rules require analytical frameworks that protect patient welfare while generating the evidence needed to advance. Statistical support at this stage shapes every subsequent development decision.
Learn moreProof-of-concept data drives funding decisions. Statistical planning at Phase II determines whether clinical signals are strong enough to justify Phase III investment, and whether endpoint strategies will withstand regulatory scrutiny at registration. Strong statistical support at this stage strengthens the development decisions that determine program progression.
Learn moreRegistration studies carry the highest regulatory stakes. Large-scale analysis, multinational submission packages and consistent statistical deliverables across global agencies require the most rigorous statistical planning, validated programming and regulatory alignment. Statistical quality at this stage directly supports the regulatory outcomes that commercial success depends on.
Learn moreBiostatistics Expertise Across Complex Therapeutic Areas
Therapeutic knowledge directly shapes endpoint strategy, biomarker planning, adaptive trial design and small-population methodologies. Disease-specific expertise strengthens statistical planning across oncology, rare disease, neurology and advanced therapies, where the scientific and regulatory demands on biostatistics are greatest.
Oncology CRO
Supporting adaptive designs, biomarker-driven programs and complex efficacy endpoints across solid tumors, hematological malignancies and immuno-oncology studies.
Learn moreRare Disease CRO
Providing specialist statistical strategies designed around small patient populations, limited datasets and the regulatory requirements of orphan drug development programs.
Learn moreNeurology CRO
Supporting long-term outcome measures, complex neurological endpoints and multi-domain assessments across CNS and neurodegenerative disease programs.
Learn moreImmunology CRO
Delivering statistical support across biologics, biosimilars and autoimmune disorder programs, handling complex endpoints, immunogenicity data and evolving regulatory requirements.
Learn moreInflammation Clinical Trials
Providing statistical expertise across inflammation clinical trials, including endpoint selection, responder analyses and composite outcome assessments for chronic inflammatory conditions.
Learn moreCell & Gene Therapy CRO
Delivering specialist statistical support for innovative ATMP trial designs, including small-N designs, durable response endpoints and advanced therapy-specific regulatory requirements.
Learn moreOrphan Drug Development
Providing statistical strategies tailored to orphan drug programs, supporting small populations, natural history analyses and regulatory submissions designed around FDA, EMA and MHRA orphan frameworks.
Learn moreSpecialist Scientific Expertise
Evestia Clinical's scientific capabilities span nearly three decades of specialist expertise in Biostatistics, Medical Affairs, Clinical Data Management, Medical Writing and Pharmacovigilance, providing sponsors with deep integrated scientific resource across every function.
For sponsors, this breadth translates directly into more experienced specialists, broader scientific collaboration, stronger submission support and greater confidence that statistical outputs are reviewed, challenged and validated by professionals who understand both the science and the regulatory context.
Integrated Clinical Data Management and Biostatistics
Integrated biometrics brings Clinical Data Management and Biostatistics together from study design through to final reporting. Collaborative planning strengthens database design, statistical analysis and submission preparation, ensuring consistency between data collection, analysis specifications and submission outputs. The results for sponsors are measurable:
- Cleaner data and faster database lock
- Fewer data queries and discrepancies
- Consistent CDISC-compliant outputs
- Stronger communication between functions
- Submission-ready evidence
- More efficient regulatory review
This integrated model strengthens submission readiness. Sponsors gain confidence in the scientific consistency of their data package, with seamless preparation that supports efficient regulatory review.
Why Sponsors Choose Evestia Clinical for Biostatistics
The Biostatistics partner a sponsor chooses shapes the scientific quality of every development decision and regulatory submission that follows. As a specialist CRO for biotech companies, Evestia Clinical combines experienced Biostatisticians, specialist Statistical Programrs and integrated biometrics expertise that strengthens the scientific integrity program success depends on.
Experienced Biostatisticians
Experienced biostatisticians strengthen study design, analytical quality and regulatory confidence. Biostatisticians with hands-on Phase I–IV & Post-Marketing knowledge across complex therapeutic areas identify design strengths and analytical opportunities early, supporting program timelines and investor confidence throughout.
CDISC & Submission Expertise
CDISC-compliant SDTM, ADaM, Define.xml and Reviewer Guides prepared to the exact standards that the FDA, EMA and MHRA expect. Submission-ready outputs from the outset support smoother regulatory review and stronger submission timelines.
SAS Programming Capability
Validated SAS® programming within documented quality environments ensures statistical outputs are accurate, reproducible and capable of withstanding regulatory scrutiny. Reliable programming is the technical foundation of submission confidence.
Integrated Data Management Support
Biostatistics and Clinical Data Management working in close alignment from database design through to final reporting ensures clean datasets, efficient database lock and seamless transition to statistical analysis. Two functions, one integrated outcome.
Therapeutic Area Expertise
Statistical strategies built around the specific scientific, regulatory and operational demands of each program. Disease-specific knowledge improves biomarker strategies, endpoint selection, adaptive design decisions and the overall quality of statistical planning.
Flexible Statistical Resource Models
Experienced Biostatisticians and Statistical Programrs available through our FSP Solutions model, supporting sponsors who require embedded expertise within their own governance structures without increasing permanent headcount.
Biostatistics for Biotech Companies
Development programs are growing in statistical complexity, and biotech sponsors need scalable biometrics expertise aligned with funding milestones and program timelines. Evestia Clinical provides embedded scientific partnership, flexible biometrics resource and integrated statistical support that grows with each program.
Operating as a genuine extension of the sponsor organization, biotech companies gain experienced Biostatisticians, specialist Statistical Programrs and scalable analytical resource aligned with program timelines and funding milestones. Available through our Full-Service CRO model or as embedded resource through FSP Solutions, teams provide scientific collaboration and capability without permanent headcount expansion.
Integrated Biostatistics and Medical Writing Support
Integrated reporting strengthens submission quality and reviewer confidence. Biostatistics, Medical Affairs and Medical Writing working in close alignment throughout the reporting process ensures scientific consistency between statistical analysis and written interpretation, supporting efficient regulatory review.
Evestia Clinical provides integrated support across statistical analysis, reporting and scientific documentation, improving submission consistency, accelerating review timelines and ensuring that statistical findings are represented with the accuracy and clarity that regulatory reviewers and publication audiences require. Working alongside Regulatory Affairs teams, our integrated model supports scientific communication quality throughout the entire submission process.
Frequently Asked Questions About Biostatistics
Explore Related Clinical Development Services
Service Pages
Development Phases
Therapeutic Expertise
Biostatistics Built for Confident Clinical Development
Reliable statistical evidence, submission-ready outputs and integrated biometrics expertise give clinical development teams the scientific confidence that confident decisions, funding milestones
and regulatory submissions require.
Whether through full-service Biostatistics, embedded FSP specialists or our Biotech CRO model, Evestia Clinical provides the scientific partnership, flexible delivery and regulatory
focus that complex programs demand.